Presseinformationen weltweit an Journalisten und Leser verbreiten
ARTES Biotechnology and Basic Pharma are almost there! The companies are nearing completion of their joint project with the production of recombinant Human Serum Albumin (rHSA) and the first vials are expected to be available this summer. ARTES, a leading Mehr
ARTES Biotechnology GmbH announced today that Volker Jenzelewski reinforces the executive board of ARTES as Managing Director beginning of the year. He will manage the company in close cooperation with Dr. Michael Piontek, Managing Director and founder of ARTES Biotechnology Mehr
company focusing on niche pharmaceutical products, are proud to announce a strategic collaboration aimed at advancing pharmaceutical innovation. Under the terms of this collaboration agreement, ARTES Biotechnology and Basic Pharma will harness their respective expertise, cutting-edge technologies, and marketing strategies Mehr
In 2002 at May 10th Michael Piontek founded ARTES as a one-man operation executing and taking care of two license deals as part of a severance agreement. He was absolute sure that this will be an interim solution only while Mehr
Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of Mehr
ARTES Biotechnology, the German-based biotech company specializing in process development for recombinant vaccines, entered development of SARS-CoV-2 vaccine candidates based on its virus-like particle (VLP) based platform technologies METAVAX® and SplitCore. METAVAX® is the company´s platform for the development of Mehr
ARTES Biotechnology and Burnet Institute recently published data on the efficient production of malaria vaccine candidates using virus-like particles (VLP) presenting malaria transmission-stage antigens, which were capable of inducing transmission-blocking antibodies. The development project funded a.o. by the PATH Malaria Mehr
ARTES Biotechnology announces the acquisition of the unique SplitCore technology developed by scientists at the University of Freiburg, Germany. Backbone of this platform is a flexible integration and presentation of foreign antigens on the surface of capsid virus like particles Mehr
ARTES Biotechnology GmbH, Germany, and Minapharm Pharmaceuticals and Chemical Industries S.A.E., Egypt, jointly announced today the formation of a new strategic business pact. Aim of this new strategic business cooperation is to jointly out-license combinations of ARTES’ and Minapharm’s respective Mehr
Under the titel: “ERA-Net EuroTransBio-8: PLURIVAX, development of a virus-like-particle (VLP) based vaccine platform and stable formulation especially suited for the veterinary applications, the EU cooperation was part of the 8th EuroTransBio call and was funded in the time period Mehr